Press releases

September 20, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 31, 2023

Ultragenyx to Participate at Investor Conferences in September

Read more

August 18, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 03, 2023

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

Read more

July 31, 2023

Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Read more

July 27, 2023

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

Read more

July 18, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

July 12, 2023

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

Read more

July 06, 2023

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Read more

June 21, 2023

Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts

Read more